Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Apyx Medical (APYX) EBT (2016 - 2026)

Apyx Medical filings provide 15 years of EBT readings, the most recent being -$1.1 million for Q4 2025.

  • On a quarterly basis, EBT rose 83.69% to -$1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$10.8 million, a 57.94% increase, with the full-year FY2025 number at -$10.8 million, up 57.94% from a year prior.
  • EBT hit -$1.1 million in Q4 2025 for Apyx Medical, up from -$1.9 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$953000.0 in Q2 2023 to a low of -$9.5 million in Q4 2023.
  • Median EBT over the past 5 years was -$4.9 million (2021), compared with a mean of -$4.8 million.
  • Biggest five-year swings in EBT: plummeted 585.83% in 2024 and later soared 83.69% in 2025.
  • Apyx Medical's EBT stood at -$1.9 million in 2021, then plummeted by 215.25% to -$5.9 million in 2022, then plummeted by 61.26% to -$9.5 million in 2023, then grew by 26.34% to -$7.0 million in 2024, then soared by 83.69% to -$1.1 million in 2025.
  • The last three reported values for EBT were -$1.1 million (Q4 2025), -$1.9 million (Q3 2025), and -$3.7 million (Q2 2025) per Business Quant data.